Brief: Icosavax Announces Topline Interim Phase 1/2 Results For Ivx-411 Against Sars-Cov-2

Icosavax

25/03/2022 13:04

March 25 (Reuters) - Icosavax Inc  ICVX.O :
    * ICOSAVAX ANNOUNCES TOPLINE INTERIM PHASE 1/2 RESULTS FOR
IVX-411
AGAINST SARS-COV-2
    * ICOSAVAX INC -REMAINS ON TRACK FOR PHASE 1/1B TOPLINE,
INTERIM
DATA FOR LEAD PROGRAM IVX-121 AGAINST RESPIRATORY SYNCYTIAL
VIRUS (RSV) IN 2Q 2022
    * ICOSAVAX INC - PHASE 1 INITIATION OF FIRST COMBINATION
VACCINE
CANDIDATE, IVX-A12 AGAINST RSV AND HUMAN METAPNEUMOVIRUS (HMPV),
ANTICIPATED IN 2H 2022
    * ICOSAVAX INC - IVX-411 WAS IMMUNOGENIC AND WELL-TOLERATED
IN
THESE INITIAL TOPLINE DATA

Source text for Eikon:  ID:nGNX85Yh1B 
Further company coverage:  ICVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))